IDE Group Holdings Plc
("IDE" or the "Company")
23 August 2021
Result of Annual General Meeting
IDE, the mid-market network, cloud and IT Managed Services provider, announces that at the Annual General Meeting of the Company held today, all resolutions put to shareholders were duly passed.
The results of the votes are set out below:
| | FOR* | AGAINST | | ||
| RESOLUTIONS | Votes | % of votes cast | Votes | % of votes cast | Abstain |
| Ordinary Resolution 1 | 129,956,626 | 100.00% | 0 | 0.00% | 2,869 |
| To receive the financial statements for the year ended 31 December 2020 together with Directors' Reports and the Auditors' Report | |||||
| Ordinary Resolution 2 | 129,681,478 | 99.79% | 274,402 | 0.21% | 3,615 |
| To approve the Remuneration Committee Report | |||||
| Ordinary Resolution 3 | 129,956,626 | 100% | 2,869 | 0.00% | 0 |
| To appoint RSM UK Audit LLP as auditors and to authorise the directors to fix their remuneration | |||||
| Ordinary Resolution 4 | N/A | N/A | N/A | N/A | N/A |
| Withdrawn | |||||
| Ordinary Resolution 5 | 129,843,916 | 99.91% | 115,579 | 0.09% | 0 |
| To re-elect Ian Smith as a director of the Company | |||||
| Ordinary Resolution 6 To authorise the directors to allot and issue shares | 129,672,466 | 99.78% | 287,029 | 0.22% | 0 |
| | |||||
| Special Resolution 7 | 129,667,717 | 99.78% | 291,778 | 0.22% | 0 |
| To authorise the directors to dis-apply pre-emption rights, as set out in the notice of meeting | |||||
| | | | | | |
| *Votes received for the resolutions includes votes allowing the Chairman's discretion. | |||||
For more information, contact:
| IDE Group Holdings Plc Andy Parker, Non-Executive Chairman
| Tel: +44 (0)344 874 1000 |
| finnCap Limited Nominated Adviser and Broker Corporate finance: Jonny Franklin-Adams/ Abby Kelly ECM: Tim Redfern/ Richard Chambers
| Tel: +44 (0)20 7220 0500 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.